• Product NameCediranib (AZD2171)
• Brief DescriptionInhibitors
• Purification99.94%
• Biological ActivityCediranib (AZD2171) is a highly potent VEGFR(KDR) inhibitor with IC50 of <1 nM, also inhibits Flt1/4 with IC50 of 5 nM/3 nM, similar activity against c-Kit and PDGFRβ, 36-, 110-fold and >1000-fold selective more for VEGFR than PDGFR-α, CSF-1R and Flt3 in HUVEC cells. Phase 3.
• Target Namec-Kit inhibitor; PDGFR inhibitor; VEGFR inhibitor
• CAS No. 288383-20-0
• Calculated MW 450.51
• Formulation C25H27FN4O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:COC1=C(OCCCN2CCCC2)C=C2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:c-Kit; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4
  Boling pt:
  Melting pt:
  Solubility:DMSO: 90 mg/mL (199.77 mM)
  Appearance:Faint Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Wedge SR, et al. Y Res. 2005 May 15; 65(10):4389-400.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting